Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells $359,406.45 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $3.51, for a total transaction of $359,406.45. Following the completion of the transaction, the chief executive officer directly owned 691,154 shares in the company, valued at approximately $2,425,950.54. The trade was a 12.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.40, for a total transaction of $217,413.00.
• On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.43, for a total transaction of $322,718.41.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.48, for a total transaction of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Stock Down 0.6%

Shares of Whitehawk Therapeutics stock traded down $0.02 on Wednesday, reaching $3.41. The stock had a trading volume of 212,634 shares, compared to its average volume of 201,638. The company has a 50 day moving average price of $3.32 and a 200 day moving average price of $2.69. Whitehawk Therapeutics, Inc. has a 1 year low of $1.39 and a 1 year high of $4.48. The stock has a market capitalization of $160.95 million, a P/E ratio of 7.26 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.21.

Institutional Trading of Whitehawk Therapeutics

Several large investors have recently bought and sold shares of the stock. Orbimed Advisors LLC purchased a new stake in Whitehawk Therapeutics during the 3rd quarter worth approximately $7,915,000. Suvretta Capital Management LLC purchased a new stake in Whitehawk Therapeutics during the 3rd quarter worth approximately $7,030,000. Acuta Capital Partners LLC acquired a new stake in Whitehawk Therapeutics during the 3rd quarter valued at approximately $6,480,000. Avoro Capital Advisors LLC acquired a new stake in Whitehawk Therapeutics during the 3rd quarter valued at approximately $5,414,000. Finally, KVP Capital Advisors LP acquired a new stake in Whitehawk Therapeutics during the 4th quarter valued at approximately $5,242,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on WHWK. Oppenheimer began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. JonesTrading assumed coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Finally, Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Whitehawk Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.50.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.